Non- HFE hemochromatosis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The term 'hemochromatosis' refers to an autosomal recessive disorder of iron metabolism associated with two mutant alleles of the HFE gene (usually leading to a Cys282Tyr mutation in the gene product) and characterized by a slow and progressive increase in plasma iron content, which, in adults, may lead to systemic iron loading of parenchymal cells (particularly hepatocytes) and, eventually, to organ disease. In rare cases, mutations in other iron-loading genes may result in a similar syndrome. The term was coined by von Recklinghausen in 1889 to describe the association at autopsy of widespread tissue injury, usually cirrhosis, with increased tissue staining for iron.1 Sheldon, in his review of all published cases, linked this term to an inherited disorder of iron metabolism that is overwhelmingly more common in males and sometimes has a familial incidence.2 A breakthrough in the history of the disease came with the recognition of its autosomal recessive nature and the location of the pathogenic gene on the short arm of chromosome 6.3, 4 These observations preceded the identification of an iron-regulating gene, now named HFE,5 that is mutated in hemochromatosis. Once the HFE gene was identified, it immediately appeared to be clear that not all patients with an inherited hemochromatosis-like phenotype carried pathogenic mutations in the HFE gene. This was particularly evident in southern European countries.6, 7 Therefore, the term 'non-HFE hemochromatosis' was coined to define hereditary iron overload in patients without pathogenic mutations in the HFE gene.8 Like 'non A-non B hepatitis', 'non-HFE hemochromatosis' was mainly a negative term, based on the ignorance of the genetic basis of the underlying disorders. Since then, unprecedented progress in animal and human iron genetics has led to the identification of new forms of primary iron overload caused by mutations in other genes involved in iron metabolism. For one of these disorders (i.e., ferroportin-associated iron overload, or ferroportin disease), epidemiology, natural history, and molecular pathogenesis are different from the corresponding characteristics in HFE hemochromatosis. These differences also may suggest a different approach to diagnosis and screening. Other disorders share pathogenic mechanisms, clinical presentation characteristics, and an autosomal recessive genetic nature (e.g., TFR2 and juvenile-associated iron overload) with classic hemochromatosis. In this context, these disorders might be considered different forms of the same clinicopathologic syndrome. Therefore, the term 'non-HFE hemochromatosis' probably should be restricted to TFR2 and juvenile-associated iron overload. In addition to classic hemochromatosis and ferrorportin disease, they define the group of 'primary iron-overload disorders', i.e., disorders due to a defect in a gene primarily involved in iron homeostasis. Other primary iron-overload diseases are the rare forms of aceruloplasminemia9, 10 and atransferrinemia.11 In the former, the lack of ferroxidase activity of plasma ceruloplasmin leads to defective iron release from tissues; the clinical picture is dominated by a neurological syndrome. In the latter, the lack of transferrin leads to increased iron absorption and excessive iron influx in parenchymal cells; severe iron-deficiency anemia is the main clinical manifestation. A unique pedigree in which iron overload is associated with a mutation in the iron-regulatory element of the H-ferritin gene also has been described.12 A distinction should be made between primary iron-overload disorders and secondary iron-overload disorders, in which iron overload is secondary to specific diseases (e.g., thalassemia or other iron-loading anemias, porphyria, etc.) or acquired factors (e.g., alcohol exposure, liver diseases, etc.). RE, reticuloendothelial; mRNA, messenger RNA; IRE, iron-responsive element. Ferroportin disease (also known as ferroportin-associated iron overload) is an autosomal dominant inherited disorder of iron metabolism that results from pathogenic mutation of the SLC40A1 gene, previously called SLC11A3. The first description of the disease was published in 1999, when an autosomal dominant form of hereditary iron overload similar to classic hemochromatosis but not linked to chromosome 6p was reported.13 Distinctive features included tissue iron accumulation predominantly in reticuloendothelial (RE) cells, steadily increasing serum ferritin levels, which were disproportionately high compared with transferrin saturation, marginal anemia, and mild organ disease.13 In 2001, a genomewide screen in the original pedigree provided evidence of linkage with respect to markers on 2q32.14 A candidate gene, SLC40A1, was identified in that region, and all affected patients were heterozygous for a 230C→A substitution; which resulted in replacement of alanine 77, a small, hydrophobic amino acid, with aspartate, a large, negatively charged amino acid; within a predicted myr
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
McKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80425-6 · Cited by 1,422
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324
A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267
Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., & Vaulont, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151179498 · Cited by 1,233
Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., & Vaulont, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215686 · Cited by 1,214
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L. E., Franchini, P. L., Dubé, M.-P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1274 · Cited by 974
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860
The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22
Camaschella, C., Roetto, A., Calì, A., De Gobbi, M., Garozzo, G., Carella, M., Majorano, N., Totaro, A., & Gasparini, P. (2000) · Nature Genetics · doi:10.1038/75534 · Cited by 803
Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.
Harris, Z. L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R. T., & Gitlin, J. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2539 · Cited by 558
Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene
Montosi, G., Donovan, A., Totaro, A., Garuti, C., Pignatti, E., Cassanelli, S., Trenor, C. C., Gasparini, P., Andrews, N. C., & Pietrangelo, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113468 · Cited by 557
Self-citationA mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans
Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H., Hiyamuta, S., Ikeda, S.-I., Shimizu, N., & Yanagisawa, N. (1995) · Nature Genetics · doi:10.1038/ng0395-267 · Cited by 463
Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis
Nicolas, G., Viatte, L., Lou, D.-Q., Bennoun, M., Beaumont, C., Kahn, A., Andrews, N. C., & Vaulont, S. (2003) · Nature Genetics · doi:10.1038/ng1150 · Cited by 311
Beaumont, C., Leneuve, P., Devaux, I., Scoazec, J.-Y., Berthier, M., Loiseau, M.-N., Grandchamp, B., & Bonneau, D. (1995) · Nature Genetics · doi:10.1038/ng1295-444 · Cited by 293
West, A. P., Bennett, M. J., Sellers, V. M., Andrews, N. C., Enns, C. A., & Bjorkman, P. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000664200 · Cited by 257
Courselaud, B., Pigeon, C., Inoue, Y., Inoue, J., Gonzalez, F. J., Leroyer, P., Gilot, D., Boudjema, K., Guguen-Guillouzo, C., Brissot, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202653200 · Cited by 245
Kato, J., Fujikawa, K., Kanda, M., Fukuda, N., Sasaki, K., Takayama, T., Kobune, M., Takada, K., Takimoto, R., Hamada, H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/321261 · Cited by 211
Gordeuk, V. R., Caleffi, A., Corradini, E., Ferrara, F., Jones, R. A., Castro, O., Onyekwere, O., Kittles, R., Pignatti, E., Montosi, G., et al. (2003) · Blood Cells, Molecules, and Diseases · doi:10.1016/s1079-9796(03)00164-5 · Cited by 198
Self-citationRegulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation
Yang, F., Liu, X.-B., Quinones, M., Melby, P. C., Ghio, A., & Haile, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201485200 · Cited by 197
Girelli, D., Corrocher, R., Bisceglia, L., Olivieri, O., De Franceschi, L., Zelante, L., & Gasparini, P. (1995) · Blood · doi:10.1182/blood.v86.11.4050.bloodjournal86114050 · Cited by 196
Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis
Zoller, H., Pietrangelo, A., Vogel, W., & Weiss, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11179-0 · Cited by 167
Self-citationTransferrin receptor 2: a new molecule in iron metabolism
Trinder, D., & Baker, E. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00258-3 · Cited by 94
Cited by
Dysmetabolic Hyperferritinemia: All Iron Overload Is Not Hemochromatosis
Makker, J., Hanif, A., Bajantri, B., & Chilimuri, S. (2015) · Case Reports in Gastroenterology · doi:10.1159/000373883 · Cited by 1,351
Papanikolaou, G., & Pantopoulos, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.06.021 · Cited by 1,070
Bacon, B. R., Adams, P. C., Kowdley, K. V., Powell, L. W., & Tavill, A. S. (2011) · Hepatology · doi:10.1002/hep.24330 · Cited by 723
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial
Atkinson, W., Sheldon, T. A., Shaath, N., & Whorwell, P. J. (2004) · Gut · doi:10.1136/gut.2003.037697 · Cited by 534
Anderson, G. J., & Vulpe, C. D. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0051-1 · Cited by 317
Metadata
- Authors
- Pietrangelo, A.
- Venue
- Hepatology
- Published
- 2004-01
- Volume
- 39
- Issue
- 1
- Pages
- 21-29
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2168688720
- Cited by
- 128
- References
- 25
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.